TrialCompass TCL
Back to results
Phase 1, Phase 2Not yet recruitingPriority 3 · Moderate priorityNCT07139353

Linperlisib Combined With Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma

ClinicalTrials.gov

Plain-language summary

This Phase 1, Phase 2 trial is testing Linperlisib and Chidamide for people whose T-cell lymphoma has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.

Who can join (key eligibility)

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Linperlisib (DRUG): Linperlisib: 80 mg or 60 mg, po, qd (phase Ib); RP2D (phase II) | Chidamide (DRUG): Chidamide: 20mg, po, biw

Drugs / treatments
Linperlisib, Chidamide
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

Linperlisib Combined With Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma

NCT07139353

Phase: Phase 1, Phase 2 | Status: Not yet recruiting | Priority: Medium

Plain-language summary

This Phase 1, Phase 2 trial is testing Linperlisib and Chidamide for people whose T-cell lymphoma has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.

Who can join

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

What's being tested

Linperlisib (DRUG): Linperlisib: 80 mg or 60 mg, po, qd (phase Ib); RP2D (phase II) | Chidamide (DRUG): Chidamide: 20mg, po, biw

Drugs / treatments: Linperlisib, Chidamide

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 54 patients

Primary endpoint: Dose-limiting toxicity (DLT) for Phase 1b; Overall response rate(ORR) for Phase 2

Ages: 18 Years to —

Start date: 2025-09-15 | Est. completion: 2029-09-01

Locations

0 US sites · 0 total

Contact

Qingqing Cai | caiqq@sysucc.org.cn | +862087342823

Sponsor: Sun Yat-sen University (OTHER)

Tags

All T-cell lymphomas · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT07139353

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.